CRMP-5-associated GTPase (CRAG), a short splicing variant of centaurin-γ3/AGAP3, is predominantly expressed in the developing brain. We previously demonstrated that CRAG, but not centaurin-γ3, translocates to the nucleus and activates the serum response factor (SRF)-c-Fos pathway in cultured neuronal cells. However, the physiological relevance of CRAG in vivo is unknown. Here, we found that CRAG/centaurin-γ3-knockout mice showed intensively suppressed kainic acid-induced c-fos expression in the hippocampus. Analyses of molecular mechanisms underlying CRAG-mediated SRF activation revealed that CRAG has an essential role in GTPase activity, interacts with ELK1 (a co-activator of SRF), and activates SRF in an ELK1-dependent manner. Furthermore, CRAG and ELK1 interact with promyelocytic leukaemia bodies through SUMO-interacting motifs, which is required for SRF activation. These results suggest that CRAG plays a critical role in ELK1-dependent SRF-c-fos activation at promyelocytic leukaemia bodies in the developing brain.
Results

Kainic acid-induced c-Fos expression is attenuated in the hippocampus in CRAG-KO mice.
We previously demonstrated that CRAG induces SRF-c-Fos activation in cultured neuronal cells 4 . However, the physiological significance of CRAG in SRF-c-Fos activation is unknown. To investigate whether CRAG activates SRF in vivo, we generated CRAG/centaurin-γ3-KO mice. Several splicing variants of centaurin-γ3/AGAP3 are identified in the NCBI database (Gene ID: 116988), including CRAG and a GTP domain-deleted isoform ( Supplementary Fig. S1A ). The GTPase domain is not required for centaurin-γ3-mediated, Arf6-mediated vesicle transport 5 , suggesting that the GTP domain has an independent and intrinsic function distinct from that of other centaurin-common regions containing the pleckstrin homology (PH), Arf Gap, and ankyrin repeat domains. CRAG/centaurin-γ3 whole-body KO (WKO) mice were established by deleting the GTPase domain ( Supplementary Fig. S1B-F) . A short GTPase domain-deleted variant of centaurin-γ3-containing centaurin-common regions was upregulated in the brains of these mutant mice ( Supplementary Fig. S1F ), suggesting that this variant compensates for the loss of function of the centaurin-common domains that occurs in centaurin-γ3. These mutant mice specifically lost the CRAG and GTPase domain functions of centaurin-γ3. In contrast to wild-type (WT) CRAG, neither the CRAG mutant lacking the GTPase domain nor the full length centaurin gamma-3 was capable of activating an SRF reporter gene ( Supplementary Fig. S1G ), these mutant mice provide a direct means of determining the physiological role of CRAG in SRF activation in vivo.
A luciferase assay in Neuro2A cells revealed that CRAG, but not centaurin-γ3, activated the c-fos promoter ( Supplementary Fig. 1H ), corroborating our previous observations. Dominant-negative SRF Δ338 mutant inhibited CRAG-induced SRF activation, indicating that CRAG activates c-fos through SRF activation. To understand the role of CRAG in c-Fos induction in vivo, we treated WKO mice with kainic acid, an agonist of the kainate-class ionotropic glutamate receptor and a strong inducer of c-Fos expression 6, 7 . We tested whether CRAG was required for c-Fos expression after kainic acid treatment. Upon phosphate-buffered saline (PBS) treatment as a control, c-Fos expression was undetectable in both the WT and WKO hippocampi ( Fig. 1A, left ). Kainic acid treatment rapidly induced c-Fos production in the WT hippocampi, whereas c-Fos induction was severely attenuated in the WKO hippocampi ( Fig. 1A, right) . Consistently, immunoblot analysis indicated that kainic acid-induced c-Fos expression was strongly suppressed in the WKO hippocampi compared to that in the WT hippocampi ( Fig. 1B) . Moreover, lentiviral vector-mediated CRAG expression rescued c-Fos induction in kainic acid-stimulated primary cultured WKO hippocampal neurons (Fig. 1C ). There was no significant difference in SRF expression between WT and WKO hippocampi, indicating that CRAG KO did not affect SRF expression ( Supplementary  Fig. S1F ). WKO mice had high death rates upon kainic acid treatment ( Fig. 1D ), which is consistent with the Figure 1 . CRAG is partially required for kainic acid-induced c-Fos expression in the mouse hippocampus. (A,B) Comparison of c-Fos expression in the hippocampus between WT and WKO mice at P18. c-Fos expressions were detected by immunostaining (A) and immunoblotting (B) in the hippocampus at 3 hours following PBS or 3 mg/kg kainic acid injection. Scale bars represent 100 μm. (C) Lentiviral expression of CRAG rescued kainic acid-induced c-Fos in primary cultured hippocampal neurons derived from WKO mice. After 1 day in vitro, cells were infected by lentiviral expression vector with CRAG. Lysates of primary hippocampal neurons of WKO mice at 3 hours following PBS or 200 μM kainic acid stimulation at 9 days in vitro were immunoblotted with indicated antibodies. (D) WKO mice exhibited a high fatality rate even after administration of low concentrations of kainic acid at P18-24. (n = 3 for 2.5 mg/kg kainic acid injection, n = 7 for 2.75 mg/kg kainic acid injection, and n = 9 for 3 mg/kg kainic acid injection). previous finding that both SRF-KO and c-fos-KO mice are vulnerable to kainic acid treatment 6, 8 . Therefore, these results suggest that CRAG is required for c-Fos induction by kainic acid stimulation in vivo.
CRAG activates SRF through interaction with ELK1.
To gain insight into the molecular mechanism of CRAG-mediated SRF activation, we focused on ELK1, a cofactor of SRF 9, 10 . Accordingly, we found that CRAG interacts with ELK1; an immunoprecipitation assay demonstrated that endogenous ELK1 was co-precipitated with endogenous CRAG in the mouse brain ( Fig. 2A ). To confirm that CRAG directly interacts with ELK1, we performed an immunoprecipitation assay on Neuro2a cells transfected with tagged CRAG and ELK1 expression vectors. CRAG was co-precipitated with FLAG-ELK1 ( Fig. 2B ) but not Myc-SRF ( Supplementary Fig. S2A ). A luciferase reporter assay further revealed that co-expression of CRAG with ELK1 dramatically increased SRF activation (by more than 40 fold) ( Fig. 2C ), suggesting that a close functional link between CRAG and ELK1. Consistently, ELK1 knockdown by siRNA reduced SRF activation and c-Fos induction by CRAG ( Fig. 2D,F ). Immunoblot analysis revealed slightly enhanced induction of c-Fos by CRAG and ELK1 co-expression (Figs. 2E and S2B), although the synergistic effect was much smaller than that in the SRF-driven luciferase reporter assay using pSRF-Luc. Similarly, a luciferase assay using c-fos promoter revealed c-fos activation of (although less than 2 times that with CRAG alone) by co-expression of CRAG and ELK1 ( Supplementary Fig. S2C ). Therefore, c-Fos induction likely becomes saturated upon SRF activation by the overexpression of CRAG alone. Taken together, these findings indicate that CRAG activates SRF-c-Fos through ELK1. Various CRAG mutants, which were unable to translocate to the nucleus, failed to synergistically activate SRF with ELK1 ( Supplementary Fig. S2D ). To confirm the ELK1-dependent SRF activation by CRAG, we examined the effect of the ELK1 ΔETS mutant, which lacks transcriptional activity for SRF, on CRAG-induced SRF activation. As expected, ELK1 ΔETS inhibited SRF activation induced by CRAG ( Supplementary Fig. S2E ). Next, we examined the effects of other ELK-family members on CRAG-mediated SRF activation: CRAG synergistically activated SRF with ELK4 but not with ELK3 ( Supplementary Fig. S2F ). ELK1 has been shown to be activated through phosphorylation by ERK, JNK, or p38 9 . Accordingly, the MEK inhibitor U0126 partially blocked CRAGand ELK1-induced SRF activation ( Supplementary Fig. S2G ), suggesting that CRAG activates ELK1, at least in part, by phosphorylation through the MEK pathway. However, the non-phosphorylated ELK1 mutant S384/390A only slightly inhibited CRAG-mediated SRF activity ( Supplementary Fig. S2H ). Therefore, these results indicate that both ELK1-dependent and -independent mechanisms are involved in the CRAG-mediated SRF activation.
CRAG GTPase activity is critical for CRAG-induced SRF activation. To explore the mechanism of CRAG-induced SRF activation, we focused on the role of the CRAG GTPase domain. Previous studies show that CRAG GTPase mutant (S140N) exhibits nuclear localization and AP-1 activation 1, 4 . We generated new CRAG GTPase mutants to test whether the CRAG GTPase domain is required for SRF activation (Fig. 3A) . A luciferase assay demonstrated that WT CRAG GTPase activated SRF, whereas cells expressing CRAG GTPase mutants including CRAG K139A/S140N mutant (KASN) showed no significant SRF activation (Figs. 3B and S3A). We checked the GTP-binding ability of the KASN mutant using GTP-agarose. In contrast to WT CRAG, the KASN mutant failed to bind GTP ( Supplementary Fig. S3B ,C). Moreover, CRAG GTPase mutants had no synergistic effect on ELK1-mediated SRF activation. Thus, GTPase activity in CRAG is critical for SRF activation through ELK1 (Fig. 2C ). Furthermore, unlike CRAG-WT, which was localized to the nucleus in approximately 70% of the cells, GTPase-deleted CRAG mutants failed to translocate to the nucleus (Fig. 3C ). On the other hand, KASN predominantly localized to the nucleus (Fig. 3D) , indicating that the CRAG GTPase domain is essential for SRF activation in the nucleus. Thus, the CRAG GTPase domain regulates CRAG function.
CRAG activates SRF by interacting with PML through its SUMO-interacting motif domains. CRAG interacts with PML bodies 1 , which are also involved in SRF activation 11 . Therefore, we determined whether PML is required for CRAG-induced SRF activation. PML knockdown significantly inhibited CRAG-induced SRF activation ( Fig. 4A and Supplementary Fig. 4A ). Many SUMOylated proteins and SUMO-binding proteins accumulate in PML bodies 12 . In silico analysis using GPS-SUMO software suggested three potential SUMO-interacting motifs (SIMs) in CRAG (Fig. 4B ) that mediate non-covalent interactions with SUMO 13 . We examined the effects of these three CRAG SIM mutants (Fig. 4B ) on SRF activation. Two CRAG SIM mutants-M1 and M2-did not activate SRF ( Fig. 4C ), suggesting that these mutants might not associate with PML bodies. To test this possibility, we compared the subcellular distribution of GFP-CRAG SIM mutants (Fig. 4D) , because GFP-CRAG forms large nuclear inclusions without stimulation 1 . Consistent with our previous observations, GFP-CRAG and GFP-CRAG SIM-M3 formed large ring nuclear inclusions, whereas GFP-CRAG SIM-M1 and SIM-M2 failed to form nuclear inclusions with PML ( Fig. 4E ), indicating that SIMs in CRAG are required for the formation of CRAG nuclear inclusions and interaction with PML bodies. Given that overexpression of SUMO1 stabilizes PML bodies 14, 15 , we examined the subcellular distribution of GFP-SUMO1 ( Supplementary Fig. S4B,C) . WT CRAG induced large GFP-SUMO1 nuclear inclusions, whereas CRAG SIM-M1 and SIM-M2 did not. These results collectively suggest that CRAG SIMs play a critical role in recognition of PML bodies and SRF activation.
CRAG induces ELK1 translocation to PML bodies under MG132 treatment. Next, we examined
whether CRAG induces ELK1 translocation to PML bodies. Distinct from GFP-CRAG, CRAG requires oxidative stress or proteasome inhibition to form nuclear inclusions co-localised with PML bodies ( Supplementary  Fig. S5A,B ). GFP-ELK1 mainly localized in the nucleus under resting conditions, consistent with a previous study ( Supplementary Fig. S5C ) 16 . As expected, CRAG induced ELK1 translocation to PML bodies under MG132 treatment (Fig. 5A,B ). CRAG KASN also induced ELK1 accumulation at PML bodies, suggesting that the CRAG GTPase domain is not required for ELK1 translocation to PML bodies. Given that ELK1 also possesses a SIM domain in its C-terminal region (Fig. 5C ), we examined whether the SIM domain of ELK1 is involved in CRAG-mediated ELK1 translocation to PML bodies. As expected, mutations in ELK1 SIM significantly attenuated CRAG-mediated ELK1 translocation to PML bodies (Fig. 5D,E) , indicating that CRAG induces ELK1 translocation to PML bodies via the ELK1 SIM domain. Consistent with this result, mutations in ELK1 SIM significantly attenuated CRAG-mediated SRF activation (Fig. 5F ). Thus, these results indicate that CRAG activates SRF at least in part through ELK1 translocation to PML bodies. A schematic model of CRAG-mediated SRF activation is shown in Fig. 5G .
Methods
Mice. CRAG flox/flox mice (Accession No. CDB0630K: http://www2.clst.riken.jp/arg/mutant%20mice%20 list.html) were crossed with CAG-Cre mice 17 . The CRAG KO mice were backcrossed for at least 10 generations onto C57B/6J mice. Genotype was confirmed by tail tipping mice at around 1month. Mice were genotyped for CRAG gene using PCR primer A, 5′-CTCAGGATGACTCCCGAACTCTATACGG-3′, and ubiquitous expression of SRF, CRAG appears to be enriched in brain. In fact, the phenotypes of WKO mice differ from those of SRF-KO mice in some respects: Central nervous system (CNS)-specific SRF-KO mice exhibit a more severe phenotype than WKO mice because they die at the neonatal stage 18 . CRAG might play an important role for the brain development after birth because CRAG expression increases after birth 5 . The different expression patterns of these proteins might make differences in the phenotypes between CRAG WKO and SRF-KO mice.
We also gained insights into the molecular mechanisms of SRF activation by CRAG. We found that CRAG specifically interacts with ELK1, a cofactor of SRF; this finding is concordant with previous results showing that found CRAG induces c-Fos, which is one of the immediate early genes. Since ELK1 shuttles between nucleus and cytoplasm 16 , CRAG can interact with ELK1 inside or outside the nucleus. CRAG might be activated by various physiological stimulations that cause oxidative stress and subsequently induce SRF and c-Fos activation via ELK1.
Our study also demonstrated the regulatory mechanism of CRAG. We found that the CRAG GTPase domain is essential for SRF activation (Fig. 3) . Although the novel GTPase mutant KASN localized at the nucleus, it did not activate SRF. Because GTPase domains regulate protein-protein interactions, the CRAG GTPase domain might be crucial for forming a complex to activate SRF. Further investigation is needed to identify target protein(s) activated by the CRAG GTP-bound form. It is also important to understand how CRAG GTPase is activated in redox signalling and oxidative stress. We previously observed that endogenous CRAG is mainly localized in cytosol and forms nuclear inclusions in response to oxidative stress 1 . The distribution of GFP-CRAG is different from that of HA-CRAG and endogenous CRAG. GFP-CRAG accumulates in the nuclear inclusions associated with PML bodies without stimulation. We consider that GFP-tagging at the N-terminal of CRAG caused a conformational change of CRAG and induced active form of CRAG. This suggests an unknown modification-mediated CRAG activation and subsequent nuclear translocation. In the present study, we found that CRAG was phosphorylated at multiple sites, suggesting that CRAG GTPase is regulated by phosphorylation. However, the kinase that phosphorylates CRAG remains unknown. We are currently screening for this kinase by using the kinase inhibitor library.
PML bodies act as a signalling platform for CRAG to activate SRF cooperatively with ELK1. SRF has been shown to be modified by SUMO1 19 and regulated by PML 11 . PML is SUMOylated at three different sites and contains a SIM 15 . In addition, the SIM in PML-binding proteins is required for PML body localization. These findings are consistent with our observation that CRAG SIM is crucial for forming nuclear inclusions co-localised with PML. ELK1 also possesses a SIM domain in its C-terminal region, and CRAG induces ELK1 translocation to PML bodies through the ELK1 SIM domain (Fig. 5C ). Thus, SUMOylation and SUMO-SIM interactions constitute a regulatory mechanism of CRAG-mediated SRF activation via ELK1. Nevertheless, further investigation is needed to identify the roles of CRAG-mediated SRF activation in neuronal development and the pathogenesis of neurodegenerative diseases.
